These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

760 related items for PubMed ID: 29116469

  • 1. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
    Brianese RC, Nakamura KDM, Almeida FGDSR, Ramalho RF, Barros BDF, Ferreira ENE, Formiga MNDC, de Andrade VP, de Lima VCC, Carraro DM.
    Breast Cancer Res Treat; 2018 Feb; 167(3):803-814. PubMed ID: 29116469
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
    Tian T, Shan L, Yang W, Zhou X, Shui R.
    Hum Pathol; 2019 Feb; 84():231-238. PubMed ID: 30339969
    [Abstract] [Full Text] [Related]

  • 3. Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients.
    Zhong X, Dong Z, Dong H, Li J, Peng Z, Deng L, Zhu X, Sun Y, Lu X, Shen F, Su X, Zhang L, Gu Y, Zheng H.
    PLoS One; 2016 Feb; 11(6):e0156789. PubMed ID: 27257965
    [Abstract] [Full Text] [Related]

  • 4. Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
    Phuah SY, Looi LM, Hassan N, Rhodes A, Dean S, Taib NA, Yip CH, Teo SH.
    Breast Cancer Res; 2012 Nov 02; 14(6):R142. PubMed ID: 23116406
    [Abstract] [Full Text] [Related]

  • 5. BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.
    Vos S, Moelans CB, van Diest PJ.
    Breast Cancer Res; 2017 May 31; 19(1):64. PubMed ID: 28569220
    [Abstract] [Full Text] [Related]

  • 6. Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
    Gross E, van Tinteren H, Li Z, Raab S, Meul C, Avril S, Laddach N, Aubele M, Propping C, Gkazepis A, Schmitt M, Meindl A, Nederlof PM, Kiechle M, Lips EH.
    BMC Cancer; 2016 Oct 19; 16(1):811. PubMed ID: 27756336
    [Abstract] [Full Text] [Related]

  • 7. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    Eoh KJ, Kim HM, Lee JY, Kim S, Kim SW, Kim YT, Nam EJ.
    BMC Cancer; 2020 Mar 12; 20(1):204. PubMed ID: 32164585
    [Abstract] [Full Text] [Related]

  • 8. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
    Yamashita N, Tokunaga E, Kitao H, Hitchins M, Inoue Y, Tanaka K, Hisamatsu Y, Taketani K, Akiyoshi S, Okada S, Oda Y, Saeki H, Oki E, Maehara Y.
    Clin Breast Cancer; 2015 Dec 12; 15(6):498-504. PubMed ID: 26195437
    [Abstract] [Full Text] [Related]

  • 9. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
    Engel C, Rhiem K, Hahnen E, Loibl S, Weber KE, Seiler S, Zachariae S, Hauke J, Wappenschmidt B, Waha A, Blümcke B, Kiechle M, Meindl A, Niederacher D, Bartram CR, Speiser D, Schlegelberger B, Arnold N, Wieacker P, Leinert E, Gehrig A, Briest S, Kast K, Riess O, Emons G, Weber BHF, Engel J, Schmutzler RK, German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).
    BMC Cancer; 2018 Mar 07; 18(1):265. PubMed ID: 29514593
    [Abstract] [Full Text] [Related]

  • 10. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
    Okuma HS, Yonemori K.
    Adv Exp Med Biol; 2017 Mar 07; 1026():271-286. PubMed ID: 29282689
    [Abstract] [Full Text] [Related]

  • 11. Germline mutations of multiple breast cancer-related genes are differentially associated with triple-negative breast cancers and prognostic factors.
    Hata C, Nakaoka H, Xiang Y, Wang D, Yang A, Liu D, Liu F, Zou Q, Wei L, Zheng K, Inoue I, You H.
    J Hum Genet; 2020 Jul 07; 65(7):577-587. PubMed ID: 32029870
    [Abstract] [Full Text] [Related]

  • 12. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
    Zhu X, Shan L, Wang F, Wang J, Wang F, Shen G, Liu X, Wang B, Yuan Y, Ying J, Yang H.
    Breast Cancer Res Treat; 2015 Apr 07; 150(3):479-86. PubMed ID: 25783183
    [Abstract] [Full Text] [Related]

  • 13. Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients.
    De Brakeleer S, De Grève J, Desmedt C, Joris S, Sotiriou C, Piccart M, Pauwels I, Teugels E.
    Clin Genet; 2016 Mar 07; 89(3):336-40. PubMed ID: 26010302
    [Abstract] [Full Text] [Related]

  • 14. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
    Rashid MU, Muhammad N, Bajwa S, Faisal S, Tahseen M, Bermejo JL, Amin A, Loya A, Hamann U.
    BMC Cancer; 2016 Aug 23; 16(1):673. PubMed ID: 27553291
    [Abstract] [Full Text] [Related]

  • 15. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
    Sahnane N, Carnevali I, Formenti G, Casarin J, Facchi S, Bombelli R, Di Lauro E, Memoli D, Salvati A, Rizzo F, Sessa F, Tibiletti MG.
    Int J Mol Sci; 2020 Dec 19; 21(24):. PubMed ID: 33352687
    [Abstract] [Full Text] [Related]

  • 16. Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.
    Bodily WR, Shirts BH, Walsh T, Gulsuner S, King MC, Parker A, Roosan M, Piccolo SR.
    PLoS One; 2020 Dec 19; 15(9):e0239197. PubMed ID: 32997669
    [Abstract] [Full Text] [Related]

  • 17. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
    Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, Denkert C, Fasching PA, Blohmer JU, Jackisch C, Paepke S, Gerber B, Kümmel S, Schem C, Neidhardt G, Huober J, Rhiem K, Costa S, Altmüller J, Hanusch C, Thiele H, Müller V, Nürnberg P, Karn T, Nekljudova V, Untch M, von Minckwitz G, Schmutzler RK.
    JAMA Oncol; 2017 Oct 01; 3(10):1378-1385. PubMed ID: 28715532
    [Abstract] [Full Text] [Related]

  • 18. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
    Francies FZ, Wainstein T, De Leeneer K, Cairns A, Murdoch M, Nietz S, Cubasch H, Poppe B, Van Maerken T, Crombez B, Coene I, Kerr R, Slabbert JP, Vral A, Krause A, Baeyens A, Claes KB.
    BMC Cancer; 2015 Nov 17; 15():912. PubMed ID: 26577449
    [Abstract] [Full Text] [Related]

  • 19. Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer.
    Gupta S, Jaworska-Bieniek K, Narod SA, Lubinski J, Wojdacz TK, Jakubowska A.
    Breast Cancer Res Treat; 2014 Dec 17; 148(3):615-22. PubMed ID: 25376744
    [Abstract] [Full Text] [Related]

  • 20. Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.
    Afghahi A, Timms KM, Vinayak S, Jensen KC, Kurian AW, Carlson RW, Chang PJ, Schackmann E, Hartman AR, Ford JM, Telli ML.
    Clin Cancer Res; 2017 Jul 01; 23(13):3365-3370. PubMed ID: 28087643
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.